Dutzer, D <br/><br/>
Letter: new thresholds need to be defined when using point of care assays to monitor infliximab trough levels in IBD patients.  [electronic resource] 

 -  Alimentary pharmacology & therapeutics  06 2018 
 - 1571-1573 p.  digital 
<br/><br/> Publication Type: Letter; Comment 
<br/><br/><label>ISSN: </label>1365-2036 
<br/><br/><label>Standard No.: </label>10.1111/apt.14645  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Colitis, Ulcerative<br/>Gastrointestinal Agents<br/>Humans<br/>Inflammatory Bowel Diseases<br/>Infliximab<br/>Point-of-Care Systems